Company Overview and News
Picking a Bear of the Day today is pretty darn easy. Just throw a dart at a dartboard and you’re bound to hit one. Stocks are blowing up left and right while the market is coming under pressure, testing key technical levels. Today I’m looking at a stock which is in the airline industry. Why? Well, the airline industry ranks in the Bottom 6% of our Zacks Industry Rank. That means there are several names which have seen earnings estimates revised to the downside.
BCH AAL NEM ALGT DLPH
The Bear of the Day article is meant to be a post about how a stock became a Zacks Rank #5 (Strong Sell). Most of the time, we see a falling stock price because investors that care about fundamentals see that earnings estimates are falling. It is rare that we see a stock like Nine Energy (NINE - Free Report) rising even as estimates are falling.
STZ.B NINE CTRL STZ OUT DLPH
2018-10-15 zacks - 1
Chicago, IL – October 15, 2018 – Zacks Equity Research highlights Twilio Inc. (TWLO - Free Report) as the Bull of the Day, Delphi Technologies (DLPH - Free Report) as the Bear of the Day. In addition, Zacks Equity Research provides analysis on Netflix, Inc. (NFLX - Free Report) , IBM Corp. (IBM - Free Report) and PayPal Holdings, Inc. (PYPL - Free Report) .
WFC WFCNP NFLX PYPL DLPH TWLO VSH HEAR
2018-10-15 247wallst - 1
Stocks were indicated flat to marginally higher on Monday after last week’s sell-off was slightly tempered by Friday’s rally. While the all-time highs are still within striking distance, investors have seen lower upside from buying immediately after the big market pullbacks in 2018 than in prior years. Now those investors also have to consider how to position their investments for the rest of the year and into 2019.
WFCNP ARRS ACRX ATVI CLF DLPH AEO LULU ELAN MS WFC ABUS TRI MRO
Delphi Technologies (DLPH - Free Report) develops and designs powertrain technologies for original equipment manufacturers. It supplies a full suite of aftermarket products, including engine control modules, pumps, injectors, fuel modules, exhaust gas recirculation valves, brakes, steering and suspension.
STZ.B BUD AHBIF STZ APTV OUT DLPH
San Francisco-based Twilio Inc. (TWLO - Free Report) is a company that provides cloud communications platforms, two of which are the Programmable Communications Cloud and the Super Network. Twilio enables developers to build, scale, and operate real-time communications within its software applications.
(Oct 11): The S&P 500 fell the most since February and the Nasdaq 100 had its worst day in seven years. But while the size of the declines were a shock, Wall Street traders reported little in the way of panic.
2018-10-05 reuters - 1
(Reuters) - Delphi Technologies Plc said on Friday Chief Executive Officer Liam Butterworth was stepping down, and the auto parts supplier cut its full-year revenue forecast, sending its shares down 8 percent.
DTK GM DLPH TEN
2018-10-05 reuters - 1
(Reuters) - Auto parts supplier Delphi Technologies Plc said on Friday Chief Executive Officer Liam Butterworth was stepping down, more than ten months after taking the post.
2018-10-05 sec.gov - 2
8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549
2018-10-05 marketwatch - 1
Delphi Technologies PLC DLPH, -2.74% said Friday Chief Executive Liam Butterworth is stepping down, after less than a year in the role, to pursue other interests, and also cut its full-year revenue outlook. The engine propulsion technology company, which was spun off from Delphi Automotive in late 2017, said it named Hari Nair as interim CEO, effective immediately. The stock was still inactive in premarket trade.
2018-10-01 - Asif
Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...
2018-09-25 - Asif
Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...
2018-09-18 - Asif
Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...
Silicon Investor Message Boards
This table lists all message boards related to DLPH / Delphi Technologies PLC on message board site Silicon Investor.
|DLPH...Delphi Information Systems||DLPH...Delphi Information Systems||DLPH...Delphi Information Systems|
as of ET